Teva Pharmaceutical Industries Reports Strong Fourth Quarter Growth and Issues 2026 Guidance
Teva Pharmaceutical Industries reported fourth-quarter results that beat analyst estimates. The company also issued lower financial guidance for the 2026 year.
Insights:
Teva Pharmaceutical Industries Ltd. announced its fourth-quarter financial results on Wednesday, reporting an adjusted diluted profit that significantly exceeded analyst expectations. For the period from October to December, the company based in IL 
ILearned $0.96 per diluted share excluding one-time items. This figure represents a notable increase from the $0.71 per share reported in the same quarter a year earlier.
ILearned $0.96 per diluted share excluding one-time items. This figure represents a notable increase from the $0.71 per share reported in the same quarter a year earlier.
